光正眼科(002524) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥208,167,536.89, representing a 4.32% increase compared to ¥199,537,963.66 in the same period last year[5] - Net profit attributable to shareholders was ¥573,756.72, a significant turnaround from a loss of ¥18,726,197.86, marking a 103.06% improvement[5] - The total profit for the current period is 1,236,552.51, while the previous period recorded a total loss of 19,249,776.86[21] - The company reported a net loss of CNY 473,792,571.21 for the first quarter, slightly improved from a loss of CNY 474,366,327.93 in the previous year[20] - The net profit for the current period is 741,381.28, compared to a net loss of 19,115,670.01 in the previous period[21] Cash Flow - The net cash flow from operating activities was -¥9,775,894.88, a decline of 59.33% from -¥6,135,808.25 in the previous year[10] - Operating cash flow net amount is -9,775,894.88, compared to -6,135,808.25 in the previous period, indicating a decline in cash flow from operations[22] - The total cash inflow from operating activities is 196,051,767.32, down from 200,747,384.16 in the previous period[22] - The total cash outflow from operating activities is 205,827,662.20, slightly decreased from 206,883,192.41 in the previous period[22] - The cash flow from financing activities net amount is 22,941,753.89, a significant improvement from -17,623,697.80 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,268,648,780.94, up 0.83% from ¥1,258,163,006.60 at the end of the previous year[5] - The total assets as of March 31, 2025, amounted to CNY 1,268,648,780.94, compared to CNY 1,258,163,006.60 at the beginning of the period, indicating a slight increase of about 0.7%[20] - The total liabilities increased to CNY 1,149,381,615.33 from CNY 1,140,864,832.23, which is an increase of approximately 0.1%[20] Research and Development - Research and development expenses increased by 113.62% to ¥625,006.00, indicating a focus on enhancing innovation[10] - The company’s research and development expenses for the quarter were CNY 625,006.00, up from CNY 292,573.94 in the previous year, indicating an increase of approximately 113.3%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 47,404, with the largest shareholder holding 24.91% of the shares[11] - The company received government subsidies amounting to ¥89,705.03, contributing positively to its financial performance[8] Other Financial Metrics - The weighted average return on equity improved to 0.50% from -6.84% year-on-year[5] - The company has no other non-recurring profit and loss items that meet the definition of non-recurring profit and loss[9] - The company completed a capital increase of CNY 40 million for its subsidiary, Shanghai New Vision East District Eye Hospital, raising its registered capital to CNY 100 million[12] - The company recorded a credit impairment loss of 1,201,040.93, compared to 518,951.32 in the previous period[21] - The company received cash from minority shareholders amounting to 400,000.00 during the current period[25] - The company's cash and cash equivalents increased to CNY 80,988,350.96 from CNY 67,688,828.82, reflecting a growth of approximately 19.5%[16] - Cash and cash equivalents at the end of the period amount to 77,659,375.11, an increase from 41,598,822.55 in the previous period[25] - The company reported a basic earnings per share of 0.00, compared to a diluted loss per share of -0.04 in the previous period[21] - The total operating costs decreased to CNY 210,803,000.59 from CNY 222,617,873.47, showing a reduction of about 5.3%[19] - The company’s inventory increased to CNY 31,990,843.46 from CNY 26,376,965.56, reflecting a growth of about 21.5%[16] - The company’s long-term equity investments stood at CNY 12,583,281.50, a marginal increase from CNY 12,540,835.87 at the beginning of the period[16]